Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.36 +1.1%	$47.45	$39.93 ▼ $63.33	$96.38B	0.36	12.82 million shs	10.87 million shs
CSLLY CSL	$79.89 +1.0%	$78.95	$70.22 ▼ $109.00	$77.37B	0.79	88,869 shs	54,280 shs
GSK GSK	$38.34 +0.1%	$38.97	$31.72 ▼ $44.67	$78.49B	0.5	4.99 million shs	4.80 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.96%	+1.85%	-4.72%	-5.24%	+17.06%
CSLLY CSL	+0.99%	-0.63%	+3.03%	+2.50%	-23.70%
GSK GSK	+0.12%	+0.33%	-6.08%	+7.46%	-2.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.9136 of 5 stars	3.2	3.0	4.2	4.0	3.1	3.3	1.3
CSLLY CSL	1.5108 of 5 stars	0.0	5.0	1.7	0.0	1.1	0.0	1.3
GSK GSK	1.7967 of 5 stars	1.1	3.0	2.5	0.0	2.1	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$57.69	21.80% Upside
CSLLY CSL	4.00	Strong Buy	N/A	N/A
GSK GSK	2.11	Hold	$37.38	-2.51% Downside

Current Analyst Ratings Breakdown

Latest BMY, GSK, and CSLLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
4/15/2025	GSK GSK	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$47.64B	2.02	$5.95 per share	7.96	$8.08 per share	5.86
CSLLY CSL	$14.80B	5.23	$4.02 per share	19.89	$20.07 per share	3.98
GSK GSK	$40.10B	1.96	$5.59 per share	6.86	$8.07 per share	4.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.74	7.78	2.38	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
CSLLY CSL	$2.64B	N/A	0.00	19.53	1.71	N/A	N/A	N/A	8/19/2025 (Estimated)
GSK GSK	$3.29B	$1.94	19.76	8.24	1.54	9.89%	48.82%	11.15%	7/30/2025 (Estimated)

Latest BMY, GSK, and CSLLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
7/30/2025	Q2 2025	GSK GSK	$1.12	N/A	N/A	N/A	$7.92 billion	N/A
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.24%	N/A	92.88%	17 Years
CSLLY CSL	$1.20	1.50%	N/A	N/A	N/A
GSK GSK	$1.71	4.46%	N/A	88.14%	N/A

Latest BMY, GSK, and CSLLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
CSLLY CSL	0.45	1.86	0.85
GSK GSK	1.21	0.87	0.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
GSK GSK	15.74%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
CSLLY CSL	N/A
GSK GSK	10.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
CSLLY CSL	32,698	968.42 million	N/A	Not Optionable
GSK GSK	68,629	2.05 billion	1.84 billion	Optionable

BMY, GSK, and CSLLY Headlines

Recent News About These Companies

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

July 14 at 11:16 AM | zacks.com

US FDA to review GSK bid to extend use of respiratory virus drug

July 14 at 6:35 AM | sharecast.comS

FDA accepts application for GSK's Arexvy, Ashmore assets under management up $1.4bn in Q4

July 14 at 6:35 AM | sharecast.comS

GSK seeks FDA green light for expanded use of RSV vaccine Arexvy

July 14 at 6:35 AM | lse.co.uk

Kathmere Capital Management LLC Acquires Shares of 7,463 GSK PLC Sponsored ADR (NYSE:GSK)

July 14 at 5:06 AM | marketbeat.com

GSK PLC Sponsored ADR (NYSE:GSK) Shares Acquired by Cerity Partners LLC

July 14 at 4:52 AM | marketbeat.com

Brown Advisory Inc. Trims Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

July 14 at 4:16 AM | marketbeat.com

GSK seeks FDA nod for expanded use of RSV vaccine in adults

July 14 at 2:42 AM | reuters.com

GSK PLC Sponsored ADR (NYSE:GSK) Shares Acquired by Envestnet Asset Management Inc.

July 11, 2025 | marketbeat.com

GSK’s Promising Phase 2b Study on Atopic Dermatitis Treatment

July 10, 2025 | tipranks.com

GSK’s Belimumab Study: A Potential Game-Changer for SSc-ILD Treatment

July 10, 2025 | tipranks.com

GSK advances Thursday, outperforms market

July 10, 2025 | marketwatch.com

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

July 10, 2025 | businesswire.com

Good news for GSK’s next generation asthma drug - pharmaphorum

July 9, 2025 | pharmaphorum.comP

GSK buys efimosfermin alfa from Boston Pharma for USD 2 billion

July 9, 2025 | medicaldialogues.inM

GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

July 9, 2025 | zacks.com

Moloney Securities Asset Management LLC Purchases Shares of 44,679 GSK PLC Sponsored ADR (NYSE:GSK)

July 9, 2025 | marketbeat.com

GSK’s Promising Phase 2b Study on Atopic Dermatitis Treatment

July 8, 2025 | tipranks.com

GSK acquires efimosfermin alfa from Boston Pharma for $2bn

July 8, 2025 | finance.yahoo.com

May Hill Capital LLC Buys New Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

July 8, 2025 | marketbeat.com

Hourglass Capital LLC Makes New Investment in GSK PLC Sponsored ADR (NYSE:GSK)

July 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, GSK, and CSLLY Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.36 +0.50 (+1.07%)

Closing price 07/14/2025 03:59 PM Eastern

Extended Trading

$47.35 -0.01 (-0.02%)

As of 07/14/2025 07:52 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$79.89 +0.78 (+0.99%)

As of 07/14/2025 03:58 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$38.34 +0.06 (+0.15%)

Closing price 07/14/2025 03:59 PM Eastern

Extended Trading

$38.40 +0.07 (+0.18%)

As of 07/14/2025 07:55 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time